PLYMOUTH MEETING, Pa., Sept. 30, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the appointment of Jennifer Laux as Vice President, Commercial. In this position she will be charged with the development of Inovio's commercialization strategy for its growing portfolio of oncology and infectious disease DNA immunotherapies. As Inovio advances its lead program into phase III, Ms. Laux will direct commercial development for the company's immunotherapies to treat HPV and the pre-cancers and cancers caused by this infection.
Ms. Laux has over 20 years of experience in life sciences, strategic consulting, and marketing, including leadership of multi-billion dollar franchises. She recently served as Vice President, Cardiovascular Marketing, at Boehringer Ingelheim. Ms. Laux spent most of her career at Merck & Co., where she led US marketing for the cardiovascular franchise and held marketing leadership positions in Merck's oncology, specialty, and women's health businesses. Her international experience includes marketing for Procter & Gamble in Brussels and Elizabeth Arden in Paris. Ms. Laux holds a MBA in Marketing from The Wharton School, a MA in International Studies from the University of Pennsylvania, and a BA in International Relations from Georgetown University.
Dr. J. Joseph Kim, Inovio's President and CEO, said: "I'm pleased to welcome Jennifer to Inovio as we advance into phase III and invest in maximizing the commercial opportunity for our innovative pipeline of DNA immunotherapies. Jennifer's significant experience in building successful global franchises coupled with her strong leadership will be a driving force in bringing our immunotherapies to patients who most need them and in growing the company."
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing the fight against cancer and infectious diseases. Our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of cancer immunotherapies and clinical studies, the company is advancing a growing product pipeline. Partners and collaborators include Roche, the University of Pennsylvania, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, US Dept. of Homeland Security, and University of Manitoba. For more information, visit www.inovio.com.
This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immune therapy and vaccine products, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2013, our Form 10-Q for the quarter ended June 30, 2014, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.
Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, email@example.com
Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, firstname.lastname@example.org
SOURCE Inovio Pharmaceuticals, Inc.